Treatment of acute pancreatitis

Drugs

Volumn 69, Issue 5, 2009, Pages 505-514

  Andersson, Roland ^a   Swrd, Anna ^a   Tingstedt, Bobby ^a   Kerberg, Daniel ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CARBAPENEM; CYTOKINE; FLUDROCORTISONE; GABEXATE; GLUCOSE; GLUTAMINE; HYDROCORTISONE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LEXIPAFANT; OCTREOTIDE; PLACEBO; PROBIOTIC AGENT; SOMATOSTATIN;

ACUTE PANCREATITIS; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIET RESTRICTION; ENTERIC FEEDING; FEASIBILITY STUDY; FLUID RESUSCITATION; HUMAN; INTENSIVE CARE; INTERVENTION STUDY; ISCHEMIA; MEDICAL CARE; MICROCIRCULATION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PREDICTION; REPERFUSION INJURY; REVIEW;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; ENTERAL NUTRITION; FLUID THERAPY; HUMANS; PANCREATITIS; PROBIOTICS;

EID: 64949128298     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969050-00001     Document Type: Review

References (87)

1. Andersson R, Andersson B, Haraldsen P, et al. Incidence, management and recurrence rate of acute pancreatitis. Scand J Gastroenterol 2004; 39: 891-4
2. Appelros S, Borgström A. Incidence aetiology, and mortality rate of acute pancreatitis over 10 years in a defined urban population in Sweden. Br J Surg 1999; 86: 465-70
3. Wilson C, Imrie CW. Changing patterns of incidence and mortality from acute pancreatitis in Scotland 1961-1985. Br J Surg 1990; 77: 731-4
4. Andersson B, Olin H, Eckerwall G, et al. Severe acute pan-creatitis-outcome following a primarily non-surgical regime. Pancreatology 2006; 6: 536-41
5. Yousaf M, McCallion K, Diamond T. Management of severe acute pancreatitis. Br J Surg 2003; 90: 407-20
6. Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the surgical management of acute pancreatitis. Pancreatology 2002; 2: 565-73
7. Beger HG, Bitner R, Block S, et al. Bacterial contamination of pancreatic necrosis: a prospective clinical study. Gastro-enterology 1986; 91: 433-8
8. Mier J, Leon EL, Castillo A, et al. Early versus late necrosectomy in severe necrotizing pancreatitis. Am J Surg 1997; 173: 71-5
9. Hartvig W, Maksan SN, Foitzik T, et al. Reduction in mortality with delayed surgical therapy of severe pancreatitis. J Gastrointest Surg 2002; 6: 481-7
10. Johnson CD. UK Guidelines for the management of acute pancreatitis. Gut 2005; 54 Suppl. 3: 1-9
11. Verner J, Feuerbach S, Uhl W, et al. Management of acute pancreatitis: from surgery to interventional intensive care. Gut 2005; 54: 426-36
12. Eckerwall G, Olin H, Andersson B, et al. Fluid resuscitation and nutritional support during severe acute pancreatitis in the past: what have we learned and how can we do better? Clin Nutr 2006; 25: 497-504
13. Menger MD, Pluschyk T, Volman B. Microcirculatory de-rangements in acute pancreatitis. J Hepatobiliary Pancreat Surg 2001; 8: 187-94
14. De Beaux AC, Goldie AS, Ross JA, et al. Serum con-centration of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996; 3: 349-53
15. Robert JH, Frossad JL, Mermillod B, et al. Early prediction of acute pancreatitis: prospective study comparing computed tomography scan, Ranson, Glasgow, acute physiology, and chronic health evaluation II scores, and various serum markers. World J Surg 2002; 26: 612-9
16. Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol 2002; 97: 1309-18
17. Bloom T, Maisonneuve P, Lowenfels AB, et al. Fatal out-come in acute pancreatitis: its occurrence and early prediction. Pancreatology 2001; 1: 237-41
18. Bradley III E. A clinically based classification system for acute pancreatitis. Arch Surg 1993; 128: 586-90
19. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut 2004; 53: 1340-4
20. Beger HG, Rau BM. Severe acute pancreatitis: clinical course and management. World J Gastroenterol 2007; 13: 5043-51
21. Ammori BJ, Leeder PC, King RF, et al. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure and mortality. J Gastrointest Surg 1999; 3: 252-62
22. Juvonen PO, Alhava EM, Takala JA. Gut permeability in patients with acute pancreatitis. Scand J Gastroenterol 2000; 35: 1314-8
23. Isenman R, Bau B, Beger HG. Bacterial infection and extent of prognosis are determinants of organ failure in patients with acute necrotizing pancreatitis. Br J Surg 1999; 86: 1020-4
24. Eckerwall G, Andersson R. Early enteral nutrition in severe acute pancreatitis-a way of providing nutrients, gut barrier protection, immunomodulation, or all of them? Scand J Gastroenterol 2001; 36: 449-58
25. Marik PE, Zaloga GP. Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis. BMJ 2004; 328: 1407-12
26. Eatock FC, Brombacher GD, Steven A, et al. Nasogastric feeding in severe acute pancreatitis. Int J Pancreatol 2000; 28: 23-9
27. Eckerwall G, Axelsson JB, Andersson R. Early nasogastric feeding in predicted severe acute pancreatitis-a clinical randomized study. Ann Surg 2006; 244: 959-67
28. Eckerwall G, Tingstedt B, Bergenzaun P, et al. Immediate oral feeding reduced length of hospital stay in patients with mild acute pancreatitis: a randomized clinical study. Clin Nutr 2007; 26: 758-63
29. Griffiths RD, Jones C, Palmer TE. Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition 1997; 13: 295-302
30. Novak F, Heyland DK, Avenell A, et al. Glutamine sup-plementation and serious illness: a systemic review of the evidence. Crit Care Med 2002; 30: 2022-9
31. Heyland DK, Novak F, Drover JW, et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001; 286: 944-53
32. Olah A, Belagy T, Issekutz A, et al. A randomized clinical trial of specific lactobacillus and fiber supplements to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 89: 1103-7
33. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-9
34. Andersson R. Probiotics in acute pancreatitis. Br J Surg 2008; 95: 941-2
35. Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: a meta-analysis. J Gastrointest Surg 1998; 2: 496-503
36. Bassi C, Mangiante G, Falconi M, et al. Prophylaxis for septic complications in acute necrotizing pancreatitis. J Hepato-Biliary Pancreat Surg 2001; 8: 211-5
37. Isenmann R, Schwarz M, Raub E, et al. Characteristics of infection with Candida species in patients with necrotizing pancreatitis. World J Surg 2002; 26: 372-6
38. Heinrich S, Schafer M, Rousson V, et al. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 2006; 243: 154-68
39. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006; 93: 674-84
40. Delinger EP, Tellade JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg 2007; 245: 674-83
41. Isenmann R, Ruinzi M, Kron M, et al. Prophylactic anti-biotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004; 126: 997-1004
42. Cavallini G, Frulloni L. Somatostatin and octreotide in acute pancreatitis: the never-ending story. Dig Liver Dis 2001; 33: 192-201
43. Uhl W, Büchler MW, Malfertheiner P, et al. A randomized, double- blind, multi-center trial of octreotide in moderate to severe acute pancreatitis. Gut 1999; 45: 97-104
44. McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol 1997; 21: 13-9
45. Bonhamn MJ, Abu-Zidan FM, Simovich MO, et al. Early ascorbic acid depletion is related to the severity of acute pancreatitis. Br J Surg 1999; 86: 1296-301
46. Schulz HU, Niederau C, Klonowski-Stumpe H, et al. Oxi-dative stress in acute pancreatitis. Hepatogastroenterology 1999; 46: 2736-50
47. Wang XD, Deng XM, Haraldsen P, et al. Antioxidant and calcium channel blockers counteract endothelial barrier injury induced by acute pancreatitis in rats. Scand J Gastroenterol 1995; 30: 1129-36
48. Büchler M, Malfartheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104: 1165-70
49. Schmid S, Uhl W, Büchler MW. Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. Scand J Gastroenterol 1996; 219 Suppl: 47-50
50. Andriulli A, Leandro G, Clemente R, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998; 12: 237-45
51. Chen HM, Chen JC, Hwang TL, et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47: 147-1150
52. Budzynska A, Marek T, Nowak A, et al. The prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33: 766-72
53. Barzilai A, Ryback BJ, Medina JA, et al. The morphological changes of the pancreas in the hypovolemic shock and the effect of pretreatment with steroids. Int J Pancreatol 1987; 2: 23-32
54. Matsumura M, Kakishita H, Suzuki M, et al. Dex-amethasone suppresses iNOS gene expression by inhibiting NF-kappaB in vascular smooth muscle cells. Life Sci 2001; 69: 1067-77
55. Van Leeuwen HJ, van der Bruggen T, van Asbeck BS, et al. Effect of corticosteroids on nuclear factor-kappaB activation and hemodynamics in late septic shock. Crit Care Med 2001; 29: 1074-7
56. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71
57. Tsukahara Y, Morisaki T, Horita Y, et al. Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis. Ann Surg 1999; 229: 385-92
58. O'Donovan DA, Kelly CJ, Abdih H, et al. Role of nitric oxide in lung injury associated with experimental acute pancreatitis. Br J Surg 1995; 82: 1122-6
59. Werner J, Fernandez-Del Castillo C, Rivera JA, et al. On the protective mechanisms of nitric oxide in acute pancreatitis. Gut 1998; 43: 401-7
60. Nishino T, Watanabe S, Oyama H, et al. Endothelial nitric oxide synthase inhibitor aggravates CDL-induced acute pancreatitis in rats. Pancreas 1999; 19: 390-400
61. Ayub K, Serracino-Inglott F, Williamson RC, et al. Expression of inducible nitric oxide synthase contributes to the development of pancreatitis following pancreatic ischaemia and reperfusion. Br J Surg 2001; 88: 1189-93
62. Gukovsky I, Gukovskaya AS, Blenman TA, et al. Early NF-kappaB activation is associated with hormone-induced pancreatitis. Am J Physiol 1998; 275: 1402-14
63. Satoh A, Shimosegawa T, Fujiita M, et al. Inhibition of nuclear factor-kappaB activation improves the survival of rats with taurocholate pancreatitis. Gut 1999; 44: 253-8
64. Dunn JA, Li C, Ha T, et al. Therapeutic modification of nuclear factor kappaB binding activity and tumor necrosis factor-alpha gene expression during acute biliary pancreatitis. Am Surg 1997; 63: 1036-43
65. Leser HG, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects the severity in acute pancreatitis. Gastroenterology 1991; 101: 782-5
66. Viedma JA, Perez-Mateo M, Dominguez JE, et al. The role of interleukin-6 in acute pancreatitis: comparison with C-reactive protein and phospholipase A. Gut 1992; 33: 1264-7
67. Berney T, Gasche Y, Robert J, et al. Serum profiles of interleukin-6, interleukin-8 and interleukin-10 in patients with severe and mild acute pancreatitis. Pancreas 1999; 18: 371-7
68. Osman MO, Jacobsen NO, Kristensen JU, et al. IT 9302 a synthetic interleukin-10 agonist, diminishes acute lung injury in rabbits with acute necrotizing pancreatitis. Surgery 1998; 124: 584-92
69. Rongione AJ, Kusske AM, Reber HA, et al. Interleukin-10 reduces circulating levels of serum cytokines in experimental pancreatitis. J Gastrointest Surg 1997; 1: 159-66
70. Osman MO, Kristensen JU, Jacobsen NO, et al. A monoclonal anti-interleukin 8 antibody (WS-4) inhibits cytokine response and acute lung injury in experimental severe acute necrotising pancreatitis in rabbits. Gut 1998; 43: 232-9
71. Paszkowski AS, Rau B, Mayer IM, et al. Therapeutic application of caspase 1/interleukin-1beta-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis. Ann Surg 2002; 235: 68-76
72. Frossard JL, Saluja A, Bhagat L, et al. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology 1999; 116: 694-701
73. Folch E, Salas A, Panes J, et al. Role of P-selectin and ICAM-1 in pancreatitis-induced lung inflammation in rats: significance and oxidative stress. Ann Surg 1999; 230: 792-8
74. Hartwig W, Jimenez RE, Fernandez-Del Castillo C, et al. Expression of the adhesion molecule Mac-1 and L-selectin on neutrophils in acute pancreatitis is protease- and complement-dependent. Ann Surg 2001; 233: 371-8
75. Wang XD, Sun ZW, Börjesson R, et al. Inhibition of platelet-activating factor, intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 reduces experimental pancreatitis- associated gut endothelial barrier dysfunction. Br J Surg 1999; 6: 411-6
76. Werner J, Z'gragen K, Fernández-Del Castillo C, et al. Specific therapy for local and systemic complications of acute pancreatitis with monoclonal antibodies against ICAM-1. Ann Surg 1999; 226: 834-42
77. Kingsnorth AN, Galloway SW, Formela LJ. Randomized doubled-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995; 82: 1414-20
78. McKay CJ, Curran F, Sharpies C, et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997; 84: 1239-43
79. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double-blind, randomized, placebo-controlled study of a platelet-activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001; 48: 62-9
80. Larvin M, Ammori B, McMahon J, et al. A double-blind, randomized, placebo-controlled multi-center trial to evaluate efficacy and safety of two doses of lexipafant in acute pancreatitis therapy [abstract]. Pancreatology 2001; 1: 279-80
81. Colak T, Ipek T, Paksoy M, et al. Effects of cefephim, g-CSF and sucralfate on bacterial translocation in experimentally induced acute pancreatitis. Surg Today 2001; 31: 502-6
82. Rao R, Prinz RA, Kazantsev GB, et al. Effects of granulocyte colony-stimulating factor in severe pancreatitis. Surgery 1996; 119:657-63
83. Ottesen LH, Bladbjerg EM, Osman M, et al. Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit. Dig Surg 1999; 16: 486-95
84. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
85. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29 Suppl.: S48-52
86. Creasey A, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 2001; 7 Suppl.: 126-9
87. Akahane K, Okamoto K, Kikuchi M, et al. Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endo-toxemia in rats. Surgery 2001; 130: 809-18